Singh Dhssraj, Thakur Akanksha, Tang W H Wilson
Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, J3-4, Cleveland, OH, 44195, USA.
Curr Heart Fail Rep. 2015 Jun;12(3):255-62. doi: 10.1007/s11897-015-0258-4.
The success achieved in advances in cancer therapy has been marred by development of cardiotoxicity, which causes significant morbidity and mortality. This has led to the development of surveillance protocols for cardiotoxicity utilizing multimodality imaging techniques and investigation of various drugs to treat and prevent cardiotoxicity in this subset of patients. Cardiac biomarkers hold important diagnostic and prognostic value in various cardiac diseases. In this review, we discuss the use of biomarkers in patients receiving chemotherapy, highlighting data behind the use of troponin, B-type natriuretic peptide, and myeloperoxidase. We also discuss the use of dexrazoxane, angiotensin-converting enzyme inhibitors, and beta blockers in the treatment and prevention of chemotherapy-induced cardiotoxicity. Cardiac biomarkers may serve an important role in selecting patients that are at high risk of cardiotoxicity and can potentially be used to guide the administration of drugs to treat and prevent cardiotoxicity.
癌症治疗进展所取得的成功因心脏毒性的出现而受到影响，心脏毒性会导致显著的发病率和死亡率。这促使人们利用多模态成像技术制定心脏毒性监测方案，并研究各种药物来治疗和预防这类患者的心脏毒性。心脏生物标志物在各种心脏疾病中具有重要的诊断和预后价值。在本综述中，我们讨论生物标志物在接受化疗患者中的应用，重点介绍肌钙蛋白、B型利钠肽和髓过氧化物酶应用背后的数据。我们还讨论了右丙亚胺、血管紧张素转换酶抑制剂和β受体阻滞剂在治疗和预防化疗引起的心脏毒性方面的应用。心脏生物标志物在选择心脏毒性高危患者方面可能发挥重要作用，并有可能用于指导治疗和预防心脏毒性药物的给药。
